

Erica M Wood

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1209963/erica-m-wood-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

3,959
citations

33
h-index

58
g-index

190
ext. papers

5,028
ext. citations

4.2
avg, IF

5.38
L-index

#	Paper	IF	Citations
174	Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia.. <i>Annals of Hematology</i> , 2022 , 1	3	
173	Reply to comment on: Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand Anaesthetists.. <i>Anaesthesia and Intensive Care</i> , 2022 , 310057X211060845	1.1	1
172	Blood Transfusion in Hospitals 2022 , 290-312		
171	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	1
170	Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Blood</i> , 2021 , 138, 4757-4757	2.2	2
169	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1690-1702	27.4	37
168	Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. <i>Vaccine</i> , 2021 , 39, 7052-7057	4.1	6
167	Patient blood management recommendations from the International Consensus Conference, Frankfurt/Main, Germany. <i>ISBT Science Series</i> , 2021 , 16, 226-230	1.1	
166	International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses. <i>Vox Sanguinis</i> , 2021 , 116, e25-e43	3.1	
165	International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Summary. <i>Vox Sanguinis</i> , 2021 , 116, 609-612	3.1	
164	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021 , 56, 2533-2543	4.4	1
163	Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand anaesthetists. <i>Anaesthesia and Intensive Care</i> , 2021 , 49, 214-221	1.1	1
162	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021 , 5, CD013600	5.2	45
161	Age of red blood cells is not associated with in-hospital mortality in massively transfused patients. <i>Journal of Trauma and Acute Care Surgery</i> , 2021 , 91, 279-286	3.3	
160	Red cell transfusions: Is less always best?: How confident are we that restrictive transfusion strategies should be the standard of care default transfusion practice?. <i>Transfusion</i> , 2021 , 61, 2195-2203	2.9	0
159	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , 2021 , 107, 497-499	3.8	0
158	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e510-e520	2	2

157	Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. <i>Vox Sanguinis</i> , 2021 , 116, 88-98	3.1	16
156	Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. <i>Gut</i> , 2021 , 70, 717-724	19.2	21
155	How should we use convalescent plasma therapies for the management of COVID-19?. <i>Blood</i> , 2021 , 137, 1573-1581	2.2	16
154	Variation in the management of Kawasaki disease in Australia and New Zealand: A survey of paediatricians. <i>Journal of Paediatrics and Child Health</i> , 2021 , 57, 646-652	1.3	
153	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. <i>Kidney International</i> , 2021 , 99, 466-474	9.9	5
152	Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial. <i>American Heart Journal</i> , 2021 , 239, 64-72	4.9	0
151	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , 2021 , 9, CD013825	5.2	39
150	Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. <i>Transfusion Medicine Reviews</i> , 2021 , 35, 73-79	7.4	1
149	Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	0
148	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. <i>The Cochrane Library</i> , 2020 , 5, CD013600	5.2	85
147	Vox Sanguinis International Forum on Hospital Transfusion Services' Response to COVID-19: Responses. <i>Vox Sanguinis</i> , 2020 , 115, e1-e17	3.1	1
146	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020 , 212, 481-489	4	66
145	Diagnostic evaluation and considerations in hypocellular bone marrow failure-A focus on genomics. <i>International Journal of Laboratory Hematology</i> , 2020 , 42 Suppl 1, 82-89	2.5	3
144	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2020 , 7, CD013600	5.2	100
143	Haematological features, transfusion management and outcomes of massive obstetric haemorrhage: findings from the Australian and New Zealand Massive Transfusion Registry. <i>British Journal of Haematology</i> , 2020 , 190, 618-628	4.5	3
142	Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. <i>British Journal of Haematology</i> , 2020 , 189, 279-290	4.5	22
141	Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. <i>American Journal of Hematology</i> , 2020 , 95, E178-E187	7.1	1
140	The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. <i>Blood</i> , 2020 , 136, 30-31	2.2	

139	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Blood</i> , 2020 , 136, 30-31	2.2	0
138	Outpatient transfusions for myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 167-174	3.1	8
137	How well does your massive transfusion protocol perform? A scoping review of quality indicators. <i>Blood Transfusion</i> , 2020 , 18, 423-433	3.6	4
136	Expression of Duffy antigen receptor for chemokines during reticulocyte maturation:using a CD71 flow cytometric technique to identify reticulocytes. <i>Immunohematology</i> , 2020 , 21, 15-20	0.4	12
135	The role of the transfusion practitioner in the management of anaemia. <i>ISBT Science Series</i> , 2020 , 15, 82-90	1.1	1
134	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2020 , 10, CD013600	5.2	64
133	Preoperative identification of cardiac surgery patients at risk of receiving a platelet transfusion: The Australian Cardiac Surgery Platelet Transfusion (ACSePT) risk prediction tool. <i>Transfusion</i> , 2020 , 60, 2272-2283	2.9	2
132	The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. <i>Transfusion</i> , 2020 , 60, 2192-2198	2.9	3
131	Critical peptic ulcer bleeding requiring massive blood transfusion: outcomes of 270 cases. <i>Internal Medicine Journal</i> , 2020 ,	1.6	1
130	Modeling the West Nile virus transfusion transmission risk in a nonoutbreak country associated with traveling donors. <i>Transfusion</i> , 2020 , 60, 2611-2621	2.9	0
129	Is Platelet Expiring Out of Date? A Systematic Review. <i>Transfusion Medicine Reviews</i> , 2020 , 34, 42-50	7.4	5
128	Approaches to understanding and interpreting the risks of red blood cell transfusion in neonates. <i>Transfusion Medicine</i> , 2019 , 29, 231-238	1.3	7
127	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e415-e424	2	6
126	Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 187-195	5.3	3
125	International haemovigilance: what have we learned and what do we need to do next?. <i>Transfusion Medicine</i> , 2019 , 29, 221-230	1.3	14
124	Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. <i>Internal Medicine Journal</i> , 2019 , 49, 358-363	1.6	4
123	The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. <i>Trials</i> , 2019 , 20, 592	2.8	12
122	Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. <i>Vox Sanguinis</i> , 2019 , 114, 853-860	3.1	1

121	The cost of blood: a study of the total cost of red blood cell transfusion in patients with β thalassaemia using time-driven activity-based costing. <i>Transfusion</i> , 2019 , 59, 3386-3395	2.9	4
120	It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. <i>Transfusion</i> , 2019 , 59, 3794-3799	2.9	29
119	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019 , 114, 79-94	3.1	22
118	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , 2019 , 49, 152-159	1.6	7
117	Microbial safety of cellular therapeutics—Lessons from over ten years—Experience in microbial safety of platelet concentrates. <i>ISBT Science Series</i> , 2019 , 14, 37-44	1.1	2
116	A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. <i>Transfusion Medicine</i> , 2019 , 29, 33-40	1.3	6
115	Heterogeneous hemoglobin lower thresholds in clinical laboratories. <i>American Journal of Hematology</i> , 2018 , 93, E142-E144	7.1	4
114	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2018 , 48, 624-636	1.6	17
113	Massive transfusions for critical bleeding: is everything old new again?. <i>Transfusion Medicine</i> , 2018 , 28, 140-149	1.3	10
112	Day or overnight transfusion in critically ill patients: does it matter?. <i>Vox Sanguinis</i> , 2018 , 113, 275-282	3.1	
111	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. <i>Nephrology</i> , 2018 , 23, 507-517	2.2	12
110	Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review. <i>Transfusion Medicine Reviews</i> , 2018 , 32, 6-15	7.4	49
109	Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. <i>Medical Journal of Australia</i> , 2018 , 208, 96	4	
108	False positive viral marker results in blood donors and their unintended consequences. <i>Vox Sanguinis</i> , 2018 , 113, 530	3.1	7
107	Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review. <i>Transfusion Medicine Reviews</i> , 2018 ,	7.4	18
106	Major haemorrhage fatalities in the Australian national coronial database. <i>EMA - Emergency Medicine Australasia</i> , 2018 , 30, 382-388	1.5	4
105	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018 , 379, 1509-1518	59.2	474
104	Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. <i>Contemporary Clinical Trials Communications</i> , 2018 , 11, 30-36	1.8	9

103	Fibrinogen is an independent predictor of mortality in major trauma patients: A five-year statewide cohort study. <i>Injury</i> , 2017 , 48, 1074-1081	2.5	69
102	Bronchial thermoplasty in severe asthma in Australia. <i>Internal Medicine Journal</i> , 2017 , 47, 536-541	1.6	14
101	Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information: summary. <i>Vox Sanguinis</i> , 2017 , 112, 487-494	3.1	1
100	Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. <i>Internal Medicine Journal</i> , 2017 , 47, 695-698	1.6	10
99	Development of RBC transfusion indications and the collection of patient-specific pre-transfusion information. <i>Vox Sanguinis</i> , 2017 , 112, e22-e47	3.1	
98	Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk. <i>Transfusion Medicine Reviews</i> , 2017 , 31, 154-164	7.4	22
97	Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. <i>Vox Sanguinis</i> , 2017 , 112, 240-248	3.1	25
96	Blood Transfusion in Hospitals 2017 , 233-253		
95	Myeloma in the Real World: What Is Really Happening?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 133-144.e1	2	22
94	Evaluation of clinical coding data to determine causes of critical bleeding in patients receiving massive transfusion: a bi-national, multicentre, cross-sectional study. <i>Transfusion Medicine</i> , 2017 , 27, 114-121	1.3	5
93	Serum ferritin as an indicator of iron status: what do we need to know?. <i>American Journal of Clinical Nutrition</i> , 2017 , 106, 1634S-1639S	7	81
92	Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. <i>Haematologica</i> , 2017 , 102, 2021-2029	6.6	28
91	Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. <i>Medical Journal of Australia</i> , 2017 , 206, 455-460	4	5
90	An international investigation into O red blood cell unit administration in hospitals: the GROUP O Utilization Patterns (GROUP) study. <i>Transfusion</i> , 2017 , 57, 2329-2337	2.9	12
89	Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a bi-national cohort study. <i>British Journal of Haematology</i> , 2017 , 179, 131-141	4.5	33
88	Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 2488-2494	2	8
87	Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. <i>Lancet Haematology</i> , 2017 , 4, e607-e614	14.6	15
86	An update on indications for platelet transfusion. <i>ISBT Science Series</i> , 2016 , 11, 170-176	1.1	

85	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. <i>BMC Medical Research Methodology</i> , 2016 , 16, 151	4.7	14
84	Haemoglobin disorders in Australia: where are we now and where will we be in the future?. <i>Internal Medicine Journal</i> , 2016 , 46, 770-9	1.6	6
83	Anemia and iron-restricted erythropoiesis in traumatic critical illness. <i>Journal of Trauma and Acute Care Surgery</i> , 2016 , 80, 538-45	3.3	7
82	Transfusion service management of sickle-cell disease patients. <i>Vox Sanguinis</i> , 2016 , 110, 288-94	3.1	2
81	Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology. <i>BMC Research Notes</i> , 2016 , 9, 457	2.3	8
80	Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study. <i>Transfusion</i> , 2016 , 56, 2455-2465	2.9	12
79	Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia: Conclusions from Clinical Trials and Current Controversies. <i>Hematology/Oncology Clinics of North America</i> , 2016 , 30, 541-60	3.1	4
78	The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results. <i>Vox Sanguinis</i> , 2016 , 111, 409-417	3.1	45
77	Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. <i>Internal Medicine Journal</i> , 2016 , 46, 71-9	1.6	29
76	The evolving role of the transfusion practitioner. <i>Transfusion Medicine Reviews</i> , 2015 , 29, 138-44	7.4	13
75	Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review. <i>Transfusion Medicine Reviews</i> , 2015 , 29, 127-37	7.4	37
74	Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. <i>Haematologica</i> , 2015 , 100, 740-7	6.6	45
73	A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. <i>The Cochrane Library</i> , 2015 , CD010981	5.2	19
72	Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. <i>Cancer</i> , 2015 , 121, 2892-9	6.4	20
71	International survey on definitions and current practices in prevention, diagnosis, management and reporting of transfusion-transmitted bacterial infections. <i>ISBT Science Series</i> , 2015 , 10, 31-40	1.1	1
70	Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). <i>BMJ Open</i> , 2015 , 5, e008938	3	9
69	Introduction of universal prestorage leukodepletion of blood components, and outcomes in transfused cardiac surgery patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015 , 150, 216-22	1.5	8
68	Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 2015 , 29, 3-13	7.4	68

67	Intravenous immunoglobulin in critically ill adults: When and what is the evidence?. <i>Journal of Critical Care</i> , 2015 , 30, 652.e9-16	4	18
66	Wrong blood in tube - potential for serious outcomes: can it be prevented?. <i>British Journal of Haematology</i> , 2015 , 168, 3-13	4.5	40
65	Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. <i>Cancer</i> , 2014 , 120, 1686-94	6.4	33
64	Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. <i>Vox Sanguinis</i> , 2014 , 107, 60-70	3.1	44
63	A dynamic mathematical model of red blood cell clinical demand to assess the impact of prolonged blood shortages and transfusion restriction policies. <i>Transfusion</i> , 2014 , 54, 2705-15	2.9	1
62	A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. <i>Cochrane Database of Systematic Reviews</i> , 2014 ,		4
61	Bacterial safety of cell-based therapeutic preparations, focusing on haematopoietic progenitor cells. <i>Vox Sanguinis</i> , 2014 , 106, 285-96	3.1	21
60	Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. <i>Transfusion</i> , 2014 , 54, 2394-403	2.9	8
59	Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial. <i>Transfusion</i> , 2014 , 54, 2385-93	2.9	48
58	Haemovigilance: concepts and frameworks. <i>ISBT Science Series</i> , 2014 , 9, 86-90	1.1	4
57	N-Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo?. <i>Transfusion</i> , 2014 , 54, 2362-3	2.9	13
56	Transfusion practice varies widely in cardiac surgery: Results from a national registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 147, 1684-1690.e1	1.5	28
55	Risk Factors for Bleeding: A Modelling Analysis of the TOPPS Randomized Controlled Trial of Prophylactic Platelet Transfusion. <i>Blood</i> , 2014 , 124, 1551-1551	2.2	6
54	Cytomegalovirus in pregnancy: to screen or not to screen. <i>BMC Pregnancy and Childbirth</i> , 2013 , 13, 96	3.2	54
53	A no-prophylaxis platelet-transfusion strategy for hematologic cancers. <i>New England Journal of Medicine</i> , 2013 , 368, 1771-80	59.2	298
52	Transfusing blood safely and appropriately. <i>BMJ, The</i> , 2013 , 347, f4303	5.9	23
51	Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards. <i>Medical Journal of Australia</i> , 2013 , 199, 397-401	4	14
50	The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. <i>Transfusion</i> , 2013 , 53, 1531-43	2.9	41

49	Education in transfusion medicine for medical students and doctors. <i>Vox Sanguinis</i> , 2013 , 104, 250-72	3.1	18
48	Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. <i>Transfusion</i> , 2013 , 53, 1714-21	2.9	16
47	Clinical trials on platelets: recent studies and what next?. <i>ISBT Science Series</i> , 2013 , 8, 119-121	1.1	
46	An update of consensus guidelines for warfarin reversal. <i>Medical Journal of Australia</i> , 2013 , 198, 198-9	4	105
45	Monosomal Karyotype Is Associated With Worse Survival Independent Of Complex Karyotype In Patients With Myelodysplastic Syndrome. <i>Blood</i> , 2013 , 122, 1523-1523	2.2	2
44	Introduction Of Universal Leucodepletion Associated With a Reduction In New Renal Failure, But Not Infection Or Mortality, In Cardiac Surgery Patients: Results From a Before and After Study. <i>Blood</i> , 2013 , 122, 788-788	2.2	1
43	A review on decision support for massive transfusion: understanding human factors to support the implementation of complex interventions in trauma. <i>Transfusion</i> , 2012 , 52, 2692-705	2.9	11
42	Bacterial contamination, screening and follow up: clinical aspects. <i>ISBT Science Series</i> , 2012 , 7, 214-219	1.1	
41	Prophylactic platelet transfusions. <i>Vox Sanguinis</i> , 2012 , 103, 159-76	3.1	9
40	Establishment of the first international repository for transfusion-relevant bacteria reference strains: ISBT working party transfusion-transmitted infectious diseases (WP-TTID), subgroup on bacteria. <i>Vox Sanguinis</i> , 2012 , 102, 22-31	3.1	31
39	The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. <i>Blood</i> , 2012 , 120, 1-1	2.2	15
38	Age of red blood cells and mortality in the critically ill. <i>Critical Care</i> , 2011 , 15, R116	10.8	73
37	Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. <i>Haematologica</i> , 2011 , 96, 1099-105	6.6	63
36	Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study. <i>Transfusion</i> , 2011 , 51, 943-8	2.9	13
35	Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. <i>Transfusion</i> , 2011 , 51, 2709-13	2.9	23
34	A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2011 , 51, 191-8	1.7	27
33	Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. <i>Annals of Hematology</i> , 2011 , 90, 1167-72	3	20
32	Bacterial Pre-Release Testing of Platelets - the Australian Red Cross Blood Service Clinical Experience. <i>Transfusion Medicine and Hemotherapy</i> , 2011 , 38, 239-241	4.2	14

31	Pathogen inactivation of platelet concentrates. <i>Vox Sanguinis</i> , 2010 , 99, 85-95	3.1	16
30	Diagnosis and management of iron deficiency anaemia: a clinical update. <i>Medical Journal of Australia</i> , 2010 , 193, 525-32	4	173
29	Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. <i>Transfusion Medicine Reviews</i> , 2010 , 24, 163-71	7.4	40
28	Hyperhaemolysis in sickle cell disease--an unusual and potentially life-threatening complication. <i>Medical Journal of Australia</i> , 2010 , 192, 281-2	4	4
27	The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. <i>Internal Medicine Journal</i> , 2009 , 39, 72-3	1.6	
26	Neonatal transfusions. <i>Vox Sanguinis</i> , 2009 , 96, 62-85	3.1	41
25	Duffy antigen expression on reticulocytes does not alter following blood loss in an autologous donation model. <i>Vox Sanguinis</i> , 2009 , 97, 268-72	3.1	1
24	Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. <i>Transfusion</i> , 2009 , 49, 2296-303	2.9	33
23	Fresh frozen plasma for cardiovascular surgery 2009 ,		1
22	Streptococcus pneumoniae septicemia associated with red blood cell transfusion. <i>Transfusion</i> , 2008 , 48, 1520-1	2.9	4
21	A 'dangerous' group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies. <i>American Journal of Transplantation</i> , 2008 , 8, 711-4	8.7	29
20	Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. <i>Transfusion</i> , 2008 , 48, 55-63	2.9	32
19	Logistics of platelet concentrates. <i>Vox Sanguinis</i> , 2007 , 92, 160-81	3.1	11
18	Detection of bacterial contamination of platelet concentrates. <i>Vox Sanguinis</i> , 2007 , 93, 260-77	3.1	34
17	Blood transfusions for iron deficiency anaemia: definitely time for a rethink!. <i>Internal Medicine Journal</i> , 2007 , 37, 283	1.6	2
16	Intravenous immunoglobulin issue policy in NSW: Australian Red Cross Blood Service clarifies 'refusal to supply'. <i>Internal Medicine Journal</i> , 2007 , 37, 735-6; author reply 736	1.6	1
15	Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?. <i>Haematologica</i> , 2007 , 92, 996-7	6.6	10
14	Choosing Donors Wisely. Reducing the Risk of Transfusion-Transmissible Viral Infection through Blood Donor Selection: The Australian Experience 2000-2006.. <i>Blood</i> , 2007 , 110, 2910-2910	2.2	

13	Can we improve the management of blood donors with nonspecific reactivity in viral screening and confirmatory assays?. <i>Transfusion Medicine Reviews</i> , 2005 , 19, 58-65	7.4	14
12	Expression of Duffy antigen receptor for chemokines during reticulocyte maturation: using a CD71 flow cytometric technique to identify reticulocytes. <i>Immunohematology</i> , 2005 , 21, 15-20	0.4	10
11	Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. <i>Medical Journal of Australia</i> , 2004 , 181, 492-7	4	271
10	International Forum: 2. <i>Vox Sanguinis</i> , 2003 , 85, 226-227	3.1	
9	Audit of a paediatric directed donation programme. <i>Journal of Paediatrics and Child Health</i> , 2003 , 39, 364-7	1.3	5
8	Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. <i>Transfusion</i> , 2001 , 41, 353-9	2.9	26
7	Methicillin-resistant Staphylococcus aureus sepsis associated with the transfusion of contaminated platelets: a case report. <i>Transfusion</i> , 2001 , 41, 1426-30	2.9	7
6	Re: Duffy phenotype does not influence the clinical severity of sickle cell disease. <i>Clinical Immunology</i> , 2001 , 98, 383-4	9	
5	Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of the P. vivax ligand required for blood-stage infection. <i>FEBS Letters</i> , 2001 , 495, 111-4	3.8	51
4	Prevention of monocyte adhesion and inflammatory cytokine production during blood platelet storage: an in vitro model with implications for transfusion practice. <i>Journal of Biomedical Materials Research Part B</i> , 2000 , 51, 147-54		9
3	Monocyte Adhesion to Platelet Concentrate Storage Bags and Cytokine Production. <i>Vox Sanguinis</i> , 2000 , 78, 133-133	3.1	1
2	The Australian Hemovigilance System 209-219		
1	Blood Transfusion in Hospitals 230-249		